Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Om P GandaJorge PlutzkySantosh K SanganalmathMaja Bujas-BobanovicAndrew KorenJonas MandelAlexia LetierceLawrence Alan LeiterPublished in: Diabetes, obesity & metabolism (2018)
Alirocumab significantly reduced LDL-C and other atherogenic lipid parameters, and was generally well tolerated in individuals with DM and ASCVD.